Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KROS

Keros Therapeutics Inc

Dec 12 • 03:35PM ET

18.48

Dollar change -50.18
Percentage change -73.09	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT VRTX ALNY IONS ARWR CARA BLUE RGNX MCRB PBYI

| Held by: IWM VTI XBI VXF IWO IBB SCHA VTWO VHT DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.21	Insider Own	25.43%	Shs Outstand	39.26M	Perf Week	-71.41%
Market Cap	748.37M	Forward P/E	-	EPS next Y	-5.39	Insider Trans	-4.63%	Shs Float	30.20M	Perf Month	-71.52%
Income	-181.57M	PEG	-	EPS next Q	-1.36	Inst Own	79.02%	Short Float	7.28%	Perf Quarter	-67.58%
Sales	0.65M	P/S	1151.34	EPS this Y	-0.06%	Inst Trans	10.69%	Short Ratio	5.64	Perf Half Y	-62.68%
Book/sh	13.57	P/B	1.36	EPS next Y	-3.51%	ROA	-40.10%	Short Interest	2.20M	Perf Year	-37.71%
Cash/sh	13.10	P/C	1.41	EPS next 5Y	4.80%	ROE	-43.82%	52W Range	27.31 - 73.00	Perf YTD	-53.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-111.11%	ROI	-33.00%	52W High	-74.69%	Beta	1.20
Dividend TTM	-	Quick Ratio	19.03	Sales past 5Y	-40.00%	Gross Margin	-75.73%	52W Low	-32.35%	ATR (14)	7.00
Dividend Ex-Date	-	Current Ratio	19.03	EPS Y/Y TTM	-5.26%	Oper. Margin	-31341.63%	RSI (14)	22.28	Volatility	6.46% 6.01%
Employees	136	Debt/Eq	0.04	Sales Y/Y TTM	8037.50%	Profit Margin	-27890.94%	Recom	1.40	Target Price	84.83
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-5.97%	Payout	-	Rel Volume	36.55	Prev Close	68.65
Sales Surprise	-	EPS Surprise	-10.27%	Sales Q/Q	4750.00%	Earnings	Nov 06 AMC	Avg Volume	389.93K	Price	18.48
SMA20	-68.17%	SMA50	-69.20%	SMA200	-66.62%	Trades		Volume	13,384,739	Change	-73.09%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	William Blair	Outperform → Mkt Perform
Today	Downgrade	TD Cowen	Buy → Hold
Today	Downgrade	BTIG Research	Buy → Neutral
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy	$96
Jun-25-24	Initiated	Oppenheimer	Outperform	$102
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight	$60
Jul-31-23	Initiated	Wedbush	Outperform	$86
Jul-26-23	Initiated	BofA Securities	Buy	$65
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy	$100
Jul-26-22	Initiated	BTIG Research	Buy	$80
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$50 → $100
May-04-20	Initiated	SVB Leerink	Outperform	$42
May-04-20	Initiated	Piper Sandler	Overweight	$35
May-04-20	Initiated	Jefferies	Buy	$37
May-04-20	Initiated	H.C. Wainwright	Buy	$50

Show Previous Ratings

Today 11:36AM	Keros Plummets 74% After Unexpected Side Effects 'Shock' Its Lead Drug (Investor's Business Daily) -73.09%
09:15AM	Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study (Investor's Business Daily)
06:02AM	Keros shares collapse on unanticipated setback for lung disease drug (BioPharma Dive)
06:00AM	Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial (GlobeNewswire)
Dec-09-24 07:30PM	Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
04:31AM	Loading…
Dec-04-24 04:31AM	Takeda licensed for anaemia therapy by Keros Therapeutics (Pharmaceutical Technology) +8.85%
Dec-03-24 12:37PM	Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst (Benzinga) +9.78%
07:00AM	Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics (Business Wire)
07:00AM	Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire)
Nov-26-24 08:00AM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Nov-06-24 04:01PM	Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire) +6.18%
08:00AM	Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Nov-05-24 09:00AM	Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-16-24 08:00AM	Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer (GlobeNewswire)
Sep-12-24 08:00AM	Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference (GlobeNewswire)
03:24PM	Loading…
Sep-05-24 03:24PM	Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Sep-03-24 08:00AM	Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial (GlobeNewswire) +5.38%
Aug-28-24 08:00AM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-07-24 11:53PM	KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024 (InvestorPlace) -6.89%
04:01PM	Keros Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-17-24 04:01PM	Keros Therapeutics Announces Leadership Updates (GlobeNewswire) -9.68%
06:00AM	Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association (GlobeNewswire)
Jun-04-24 08:00AM	Keros Therapeutics to Host a Corporate Update Conference Call and Webcast (GlobeNewswire)
Jun-03-24 08:00AM	Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 04:01PM	Keros Therapeutics Appoints Jean-Jacques Bienaime to its Board of Directors (GlobeNewswire)
04:01PM	Keros Therapeutics Appoints Jean-Jacques Bienaim to its Board of Directors (GlobeNewswire)
May-14-24 10:00AM	Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association (GlobeNewswire)
May-10-24 01:25PM	Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials (GuruFocus.com) -5.78%
May-08-24 12:54PM	KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results (GlobeNewswire)
08:00AM	Loading…
Mar-14-24 08:00AM	Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes (GlobeNewswire)
Mar-05-24 08:00AM	Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference (GlobeNewswire)
Feb-28-24 04:42PM	Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023 (GuruFocus.com)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
08:50AM	Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Feb-21-24 09:55AM	Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect? (Zacks)
Feb-12-24 08:50AM	Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why (Zacks) +7.02%
Jan-31-24 09:55AM	Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know (Zacks)
Jan-29-24 08:00AM	Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress (GlobeNewswire)
Jan-24-24 08:50AM	Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-23-24 09:55AM	Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-15-24 09:55AM	How Much Upside is Left in Keros Therapeutics, Inc. (KROS)? Wall Street Analysts Think 57.46% (Zacks)
Jan-09-24 08:00AM	Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jan-03-24 09:29PM	Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +18.47%
04:05PM	Keros Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:00AM	Keros Therapeutics to Develop KER-065 for the Treatment of Obesity (GlobeNewswire)
Dec-15-23 06:39PM	HollySys Automation, Keros Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-11-23 06:00AM	Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) -20.53%
Nov-07-23 08:00AM	Keros Therapeutics to Present at Upcoming Healthcare Conferences (GlobeNewswire)
Nov-06-23 08:00AM	Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 09:00AM	Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-04-23 08:00AM	Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-05-23 08:00AM	Keros Therapeutics to Present at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-07-23 08:00AM	Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 09:51AM	Adobe upgraded, Salesforce downgraded: Wall Street's top analyst calls (The Fly)
Jul-27-23 04:01PM	Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension (GlobeNewswire) -8.01% +6.90%
Jul-24-23 08:00AM	Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension (GlobeNewswire)
Jul-04-23 09:39AM	Keros Therapeutics (NASDAQ:KROS) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jun-12-23 08:00AM	Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire) -6.61%
Jun-09-23 10:55AM	13 Best Future Stocks for the Long-Term (Insider Monkey) -10.36%
06:00AM	Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association (GlobeNewswire)
Jun-07-23 08:00AM	Keros Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-22-23 09:00AM	Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference (GlobeNewswire)
May-11-23 04:01PM	Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association (GlobeNewswire)
May-04-23 04:01PM	Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results (GlobeNewswire)
May-01-23 12:00PM	Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-21-23 01:55PM	Why Shares of Keros Therapeutics Jumped This Week (Motley Fool)
Apr-19-23 08:00AM	Keros Therapeutics Appoints Alpna Seth, Ph.D., to its Board of Directors (GlobeNewswire)
Mar-03-23 04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +6.40% -12.00%
Mar-02-23 08:38AM	Is a Surprise Coming for Keros Therapeutics (KROS) This Earnings Season? (Zacks)
Mar-01-23 08:00AM	Keros Therapeutics to Present at Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 08:00AM	Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-25-23 06:16AM	We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely (Simply Wall St.)
Dec-23-22 12:00PM	Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-12-22 10:00AM	Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Nov-24-22 09:55AM	Wall Street Analysts Think Keros Therapeutics, Inc. (KROS) Could Surge 95%: Read This Before Placing a Bet (Zacks)
Nov-22-22 08:00AM	Keros Therapeutics to Present at Upcoming Healthcare Conferences (GlobeNewswire)
Nov-08-22 12:00PM	Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	Wall Street Analysts Believe Keros Therapeutics, Inc. (KROS) Could Rally 96%: Here's is How to Trade (Zacks)
Nov-07-22 04:01PM	Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions (GlobeNewswire)
Nov-03-22 09:00AM	Keros Therapeutics to Present at the 64th American Society of Hematology Annual Meeting and Exposition, Including Presenting Data from its Phase 2 Clinical Trials Evaluating KER-050 and KER-047 (GlobeNewswire)
07:00AM	Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-17-22 12:56PM	Shareholders have faith in loss-making Keros Therapeutics (NASDAQ:KROS) as stock climbs 10% in past week, taking one-year gain to 13% (Simply Wall St.) +5.28%
Oct-14-22 07:38PM	Why Shares of Keros Therapeutics Rose 10.2% This Week (Motley Fool)
Sep-12-22 06:00AM	Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting (GlobeNewswire)
Sep-06-22 08:00AM	Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
08:00AM	Keros Therapeutics to Present at the American Society for Bone and Mineral Research 2022 Annual Meeting (GlobeNewswire)
Aug-18-22 06:30AM	We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate (Simply Wall St.)
Aug-04-22 04:01PM	Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results (GlobeNewswire) +12.77%
Jul-20-22 09:26AM	Lexington lab building fully leased ahead of completion (American City Business Journals) +5.91%
Jun-13-22 08:00AM	Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the Pulmonary Hypertension Association International Conference and Scientific Sessions (GlobeNewswire) -5.16%
Jun-10-22 06:00AM	Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 27th Annual Congress of the European Hematology Association (GlobeNewswire) -5.74%
May-18-22 12:38PM	Keros Therapeutics Posts Preliminary Data Early-Stage KER-012 Trial (Benzinga) -16.56%
12:25PM	Keros Therapeutics Posts Encouraging Preclinical Data Of RKER-012 In Type Of High Blood Pressure (Benzinga)
06:00AM	Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers (GlobeNewswire)
May-17-22 04:01PM	Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference (GlobeNewswire)
May-12-22 04:01PM	Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association (GlobeNewswire) +6.03%
May-10-22 12:10PM	The one-year earnings decline has likely contributed toKeros Therapeutics' (NASDAQ:KROS) shareholders losses of 12% over that period (Simply Wall St.) +5.68%
May-05-22 08:00AM	Keros Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) -7.22%
Mar-09-22 04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) +7.75%

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GORDON CARL L	Director	Aug 13 '24	Sale	44.01	250,000	11,002,500	119,522	Aug 15 05:06 PM
ORBIMED ADVISORS LLC	Director	Aug 13 '24	Sale	44.01	250,000	11,002,500	119,522	Aug 15 05:01 PM
OrbiMed Genesis Master Fund, L	Shareholder	Aug 13 '24	Proposed Sale	44.84	29,400	1,318,296		Aug 13 04:12 PM
OrbiMed Private Investments VI	Shareholder	Aug 13 '24	Proposed Sale	44.84	220,600	9,891,704		Aug 13 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KROS

Keros Therapeutics Inc

Upgrade your FINVIZ experience